Agenda for Day 1 - Monday 9 November, 2026Monday, 9 November 2026

Location: Seated Lunch Area

Led by subject matter experts sharing the latest thinking, Community Conversations, delivered through a dynamic roundtable format, provide a unique opportunity to gain cutting-edge insights while fostering meaningful peer exchanges, sharing best practices, and expanding your professional network.  

Choose between:

Crafting Your Regulatory Strategy to Align with Evolving Regulatory Frameworks 
Regulatory pathways are evolving rapidly, with greater emphasis on early engagement, adaptive approaches and evidence generation across the product lifecycle. Companies that understand how to align regulatory, clinical, manufacturing and commercial strategies early will be better positioned to accelerate development, reduce risk and maximise the value of innovation. Explore how emerging regulatory frameworks are changing the route to approval, how companies can use early scientific advice and collaborative approaches to shape development strategies, and what lessons can be learned from examples of successful regulatory navigation.

Led by: Raun Kupiec, Founder & Principal, R Kupiec Consulting

From Clinical Development to Commercial Success: Integrating Global Market Access into Trial Strategy 
Examine how aligning endpoints with payer needs across diverse markets can enhance trial outcomes. Consider strategies for selecting sites that balance speed, cost, and market positioning while addressing geopolitical risks in global trials. How can organisations build robust infrastructure in emerging markets to ensure seamless integration of global market access into their trial strategies? 

Led by: Mark Reid, Founder & Managing Director, Graythan Regulatory Services

Future-Proofing Your Biomanufacturing Strategy: Integrating Manufacturing From Day One 
Consider how embedding manufacturing considerations early can accelerate commercialisation and challenge traditional downstream approaches. What strategies can organisations adopt to build scalable, competitive therapies right from the start and stay ahead in an evolving biomanufacturing landscape? 

Led by: Dan Stanton, Trade Media Relations Expert, Sartorius and Stuart Tindal, Principal Platform Manager, Sartorius

Commercialisation and Global Launch: How Do You Build a Global Commercial Success?

Commercial success no longer depends on winning the US market alone. As biotech companies increasingly prepare for launches across multiple regions, the companies that succeed globally are those that build commercial strategy early, understand local market dynamics and create the right capabilities beyond their home market. Explore what companies should do differently when preparing for international launches, how early commercial planning should begin, and the common mistakes that can limit success. Examine the strategies that have enabled biotech companies to successfully build global franchises and maximise the value of their innovations worldwide.

Led by: Dave Thomas, Senior Advisor, Venture Valuation

Attracting and Retaining Top Talent in European Biotech 
If this keeps you awake at night and as a founder, entrepreneur, C-suite officer or HR professional – let’s discuss: strategies for building a competitive workforce to lead on a global scale while addressing skill gaps through targeted training initiatives. How can fostering diversity drive innovation, and what approaches can organisations adopt to retain top talent by offering career growth opportunities and workplace flexibility? How can this become part of your success story from start-up to scale up and exit or long-term growth?

Led by: Tony Jones, CEO of One Nucleus and Oliver Schacht, Managing Director, Life Science Nord

New Models for Biotech Partnerships: Adapting to Complexity and Capital Constraints 
How are partnering strategies changing in a world of constrained capital, global competition, and increasing scientific complexity? Discover how early licensing agreements can share risks and accelerate innovation, while co-development models combine resources and expertise. Explore the potential of venture creation to drive new opportunities and examine how pharma-biotech collaborations and academic partnerships can address complex scientific challenges. 

Executing your Deal: The Power of Alliance Management

Signing your deal is just the start. True value lies in how, and how quickly, partnerships advance your mutual project or product. Let’s discuss key traits of your high-performing collaborations, strategies for alignment, fostering collaboration, planning ahead, managing conflicts…., and explore how Alliance Management adapts to the additional complexity of digital-data-driven collaborations.

Led by: Anthony and Adrien Hörning, Partners, Strategic Transactions Advisory AG

Location: Seated Lunch Area

The roundtable Community Conversations will repeat in two blocks to allow attendees to move between sessions

Choose between:

Crafting Your Regulatory Strategy to Align with Evolving Regulatory Frameworks 
Regulatory pathways are evolving rapidly, with greater emphasis on early engagement, adaptive approaches and evidence generation across the product lifecycle. Companies that understand how to align regulatory, clinical, manufacturing and commercial strategies early will be better positioned to accelerate development, reduce risk and maximise the value of innovation. Explore how emerging regulatory frameworks are changing the route to approval, how companies can use early scientific advice and collaborative approaches to shape development strategies, and what lessons can be learned from examples of successful regulatory navigation.

Led by: Raun Kupiec, Founder & Principal, R Kupiec Consulting

From Clinical Development to Commercial Success: Integrating Global Market Access into Trial Strategy 
Examine how aligning endpoints with payer needs across diverse markets can enhance trial outcomes. Consider strategies for selecting sites that balance speed, cost, and market positioning while addressing geopolitical risks in global trials. How can organisations build robust infrastructure in emerging markets to ensure seamless integration of global market access into their trial strategies? 

Led by: Mark Reid, Founder & Managing Director, Graythan Regulatory Services

Future-Proofing Your Biomanufacturing Strategy: Integrating Manufacturing From Day One 
Consider how embedding manufacturing considerations early can accelerate commercialisation and challenge traditional downstream approaches. What strategies can organisations adopt to build scalable, competitive therapies right from the start and stay ahead in an evolving biomanufacturing landscape? 

Led by: Dan Stanton, Trade Media Relations Expert, Sartorius and Stuart Tindal, Principal Platform Manager, Sartorius

Commercialisation and Global Launch: How Do You Build a Global Commercial Success?

Commercial success no longer depends on winning the US market alone. As biotech companies increasingly prepare for launches across multiple regions, the companies that succeed globally are those that build commercial strategy early, understand local market dynamics and create the right capabilities beyond their home market. Explore what companies should do differently when preparing for international launches, how early commercial planning should begin, and the common mistakes that can limit success. Examine the strategies that have enabled biotech companies to successfully build global franchises and maximise the value of their innovations worldwide.

Led by: Dave Thomas, Senior Advisor, Venture Valuation

Attracting and Retaining Top Talent in European Biotech 
If this keeps you awake at night and as a founder, entrepreneur, C-suite officer or HR professional – let’s discuss: strategies for building a competitive workforce to lead on a global scale while addressing skill gaps through targeted training initiatives. How can fostering diversity drive innovation, and what approaches can organisations adopt to retain top talent by offering career growth opportunities and workplace flexibility? How can this become part of your success story from start-up to scale up and exit or long-term growth?

Led by: Tony Jones, CEO of One Nucleus and Oliver Schacht, Managing Director, Life Science Nord

New Models for Biotech Partnerships: Adapting to Complexity and Capital Constraints 
How are partnering strategies changing in a world of constrained capital, global competition, and increasing scientific complexity? Discover how early licensing agreements can share risks and accelerate innovation, while co-development models combine resources and expertise. Explore the potential of venture creation to drive new opportunities and examine how pharma-biotech collaborations and academic partnerships can address complex scientific challenges. 

Executing your Deal: The Power of Alliance Management

Signing your deal is just the start. True value lies in how, and how quickly, partnerships advance your mutual project or product. Let’s discuss key traits of your high-performing collaborations, strategies for alignment, fostering collaboration, planning ahead, managing conflicts…., and explore how Alliance Management adapts to the additional complexity of digital-data-driven collaborations.

Led by: Anthony and Adrien Hörning, Partners, Strategic Transactions Advisory AG